AliciaKatherineMorgansMD, MPH

PubMed

• 319 citations
  Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, ...
  Thomas Powles, Tibor Csőszi, Mustafa Ozguroglu, Nobuaki Matsubara, Lajos Géczi
  The Lancet. Oncology. 2021-07-01
• 81 citations
  Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses
  Jiun-Ruey Hu, Meredith S. Duncan, Alicia K. Morgans, Jonathan D. Brown, Wouter C. Meijers
  Arteriosclerosis, Thrombosis, and Vascular Biology. 2020-01-23
• 39 citations
  Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action.
  Sumeet Bhanvadia, Sarah P. Psutka, Madeleine L. Burg, Ronald de Wit, Haryana M. Dhillon
  European Urology Oncology. 2021-04-02

Journal Articles

• Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer  
  Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS..., Ann Oncol, 1/1/2017
• Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction  
  Kanz BA, Pollack MH, Johnpulle RA, Puzanov I, Horn L, Morgans AK, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB, Journal for ImmunoTherapy of Cancer, 1/1/2016
• Optimal management of muscle-invasive bladder cancer - a review  
  Scarpato KR, Morgans AK, Moses KA, Res Rep Urol, 1/1/2015
• Disparities by race, age, and sex in the improvement of survival for major cancers: Results from the NCI Surveillance, Epidemiology, and End Results (SEER) program in ...  
  Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W, JAMA Oncology, 1/1/2015
• Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilumumab survivors at a single referral c...  
  Johnson DB, Friedman DL, Berry EG, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM, Cancer Immunol Res, 1/1/2015
• Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study  
  Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Penson DF, Prostate Cancer Prostatic Dis, 1/1/2014
• Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2  
  Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF, J Clin Invest, 1/1/2004
• Join now to see all

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: Screening and treating prostate cancer in the older patient: decision making across the clinical spectrum. 
  Page 370 - 381Morgans AK, Dale W, Briganti A2017
• Management of Prostate Cancer 
  Chapter: Pitfalls of Androgen Deprivation Therapy. 
  Page 379 - 400Morgans AK and Smith MREditors: Klein E, Jones JS.Humana Press, NJEdition 3rd,2013
• Adult Acute Lymphocytic Leukemia 
  Chapter: The Generalized Care of the Patient with Acute Lymphoblastic Leukemia 
  Page 97 - 114Mato AR, Morgans AK, Luger SMEditors: Advani AS and Lazarus HM.Humana Press, NJ2011
• Allogeneic Stem Cell Transplantation 
  Chapter: Post-transplant lymphoproliferative disorder. 
  Page 597 - 618Reshef R, Morgans AK, Tsai DEEditors: Lazarus HM & Laughlin MJ.Humana Press, NJ2010
• Join now to see all

Abstracts/Posters

• Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC).
  D.P. Petrylak, E.I. Heath, G. Sonpavde, S. George, A. Morgans, B. Eigl, J. Picus, S. Cheng, S. Hotte, E. Gartner, M. Vincent, R. Chu, B. Anand, K. Morrison, L. Jackson..., American Society of Clinical Oncology Annual Meeting, 1/1/2016
• Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).
  Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, Jarrard DF, Liu G, Morgans AK, Wong YN, Sweeney C, American Society of Clinical Oncology Annual Meeting, 1/1/2016
• Education practices in prostate cancer: A comparison of patient and caregiver experiences.
  Allen JC, Du L, Ahmed IA, Morgans AK, Cancer Survivorship Symposium: Advancing Care and Research-A Primary Care and Oncology Symposium, 1/1/2016
• Quality of life analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer.
  Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, Jarrard DF, Liu G, Morgans AK, Wong YN, Sweeney C, American Society of Clinical Oncology Genitourinary Symposium, 1/1/2016
• Patient Expectations from Treatment of Incurable Metastatic Prostate Cancer.
  Morgans AK, Du L, Ahmed IA, Penson DF, Society of Medical Decision Making Annual Meeting, 1/1/2016
• Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach.
  Morgans AK, van Bommel ACM, Stwoell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert ..., European Association of Urology Annual Congress, Plenary Session 4, Madrid, Spain, 1/24/2015
• Therapy of metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II...
  Scott T. Tagawa, Allyson J. Ocean, Elaine Lam, Wells A. Messersmith, Philip Saylor, Aditya Bardia, Julio J. Hajdenberg, Alicia K Morgans, Kevin Kalinsky, Jordan D. Ber..., American Association for Cancer Research, 1/1/2015
• Distinct side effect profiles after contemporary treatment of localized prostate cancer.
  Hoffman K, Alvarez JA, Barocas D, Koyama T, Morgans A, Phillips S, Resnick M, Penson D, American Urological Association Annual Meeting, 1/1/2015
• Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach.
  Morgans AK, van Bommel ACM, Stwoell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert ..., American Society of Clinical Oncology Genitourinary Symposium, 1/1/2015
• A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
  Palmbos PL, Feng FY, William KK, Morgans AK, Taplin ME, Agarwal N, Antonarakis ES, Twardosski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M, American Society of Clinical Oncology Genitourinary Symposium, 1/1/2015
• Influence of Age on Incident Diabetes (DM) and Cardiovascular Disease (CVD) Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy (ADT).
  AK Morgans, KH Fan, T Koyama, PC Albertsen, M Goodman, AS Hamilton, RM Hoffman, JL Stanford, AM Stroup, MJ Resnick, DA Barocas, CL Derleth, DF Penson, American Society of Clinical Oncology Annual Meeting, Health Services Track, 1/1/2014
• Influence of Age on Incident Diabetes (DM) and Cardiovascular Disease (CVD) Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy (ADT).
  AK Morgans, KH Fan, T Koyama, PC Albertsen, M Goodman, AS Hamilton, RM Hoffman, JL Stanford, AM Stroup, MJ Resnick, DA Barocas, CL Derleth, DF Penson, American Society of Clinical Oncology Genitourinary Symposium, 1/1/2014
• Pre-treatment disease-specific health-related quality of life in a contemporary prostate cancer cohort: results from CEASAR.
  M Resnick, D Barocas, A Morgans, S Phillips, V Chen, M Cooperberg, J Graff, S Greenfield, A Hamilton, K Hoffman, S Kaplan, T Koyama, A Stroup, XC Wu, D Penson, American Urologic Association Annual Meeting, 1/1/2013
• Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS).
  AK Morgans, KH Fan, T Koyama, PC Albertsen, M Goodman, AS Hamilton, RM Hoffman, JL Stanford, AM Stroup, CL Derleth, DF Penson, American Society of Clinical Oncology Genitourinary Symposium, 1/1/2013
• The burden of pre-treatment urinary, sexual, and bowel dysfunction across two decades of prostate cancer: results from PCOS and CEASAR.
  M Resnick, D Barocas, A Morgans, S Phillips, KH Fan, T Koyama, P Albertsen, V Chen, M Cooperberg, J Graff, S Greenfield, A Hamilton, K Hoffman, R Hoffman, S Kaplan, J ..., American Urologic Association Annual Meeting, 1/1/2013
• Long term treatment regret among men treated with radical prostatectomy or external beam radiation therapy for localized prostate cancer: results from the Prostate Can...
  M Resnick, KH Fan, T Koyama, K Keegan, D Barocas, A Morgans, A Hamilton, A Stroup, P Albertsen, R Hoffman, D Penson, American Urologic Association Annual Meeting, 1/1/2013
• Association between race and participatory decision making (PDM) in treatment decisions for prostate cancer (PC) management.
  D Barocas, M Resnick, A Morgans, Sharon Phillips, V Chen, M Cooperberg, J Graff, S Greenfield, A Hamilton, K Hoffman, S Kaplan, T Koyama, A Stroup, XC Wu, D Penson, American Urologic Association Annual Meeting, 1/1/2013
• Influence of Race and Comorbidity on Therapy for Prostate Cancer: Evolution Over 15 Years.
  AK Morgans, MJ Resnick, KH Fan, T Koyama, KE Hoffman, SH Kaplan, AM Stroup, R Hoffman, S Greenfield, AS Hamilton, VW Chen, XC Wu, DF Penson, DA Barocas and the PCOS an..., American Urologic Association Annual Meeting, 1/1/2013
• Osteoporosis screening among prostate cancer survivors treated with androgen deprivation therapy.
  AK Morgans, MR Smith, JA O'Malley, NL Keating, American Society of Clinical Oncology Conference, 1/1/2012
• Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
  AK Morgans, RA Morton, ML Hancock, KG. Barnette, MS Steiner, MR. Smith, American Society of Clinical Oncology Genitourinary Symposium, 1/1/2011
• Survival following resection of pancreatic cancers may not be affected by length of hospital stay or delay to initiating adjuvant chemoradiation (CRT).
  A. Morgans, D. Moghanaki, R. Mick, E. E. Furth, P. Salmon, A. Behbehani, J. Drebin, E. F. Rosato, R. Whittington, B. J. Giantonio, American Society of Clinical Oncology Conference, 1/1/2008
• Number and percentage of pathologically involved lymph nodes in patients with pancreatic adenocarcinoma predicts for overall survival in pts treated with postoperative...
  P. Salmon, D. Moghanaki, R. Mick, E. E. Furth, A. Behbehani, A. Morgans, J. Drebin, E. F. Rosato, R. Whittington, B. J. Giantonio, American Society of Clinical Oncology Conference, 1/1/2008
• Outcomes with postoperative chemoradiation in patients with gross residual disease following surgical resection of pancreatic adenocarcinoma.
  D. Moghanaki, A. Behbehani, A. Morgans, P. Salmon, E. E. Furth, W. Sun, B. J. Giantonio, J. M. Metz, E. F. Rosato, R.Whittington, American Society of Clinical Oncology Conference, 1/1/2008
• Survival following partial pancreatectomy and radiation for ampullary adenocarcinoma.
  J. C. Haynes, D. Moghanaki, A. Morgans, P. Salmon, E. E. Furth, B. J. Giantonio, J. Drebin, E. F. Rosato, R. Whittington, J. M. Metz, American Society of Clinical Oncology Conference, 1/1/2008
• Retrospective review of pts treated with adjuvant chemoradiation following resection of pancreatic adenocarcinoma.
  D. Moghanaki, P. Salmon, R. Mick, A. Bebehani, A. Morgans, E. Furth, D. G. Haller, W. Sun, J. M. Metz, R. Whittington, E. F. Rosato, American Society of Clinical Oncology Conference, 1/1/2008
• Join now to see all

Lectures

• Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US c... 
  2019 ASCO Annual Meeting - 6/1/2019
• Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Optimizing Patient-Centered Care and Follow-up in Prostate Cancer 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Annual Update in Successes and Challenges in Prostate Cancer. 
  Washington, DC - 1/28/2017
• In His Own Words: Use of Patient Reported Outcomes in Advanced Prostate Cancer. 
  St. Gallen, Switzerland - 1/10/2017
• Physical and Cognitive Effects of Systemic Therapy in Elderly Men with Prostate Cancer. 
  Chicago, IL - 1/6/2017
• Outlook on Prostate Cancer in 2016. 
  Washington, DC - 1/23/2016
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer. 
  San Francisco, CA - 1/21/2016
• Patient-Centered Treatment Decision Making in Advanced Prostate Cancer. 
  Vanderbilt University, Nashville, TN - 1/14/2016
• The Future is Now: Treatment of Advanced Prostate Cancer. 
  Nashville, TN - 1/7/2016
• Role of Systemic Therapy in Bladder Cancer. 
  Hyatt Regency, Clearwater, FL - 1/24/2015
• Prostate Cancer: A Treatment Landscape in Flux. 
  Nashville, TN - 1/22/2015
• Outlook on Prostate Cancer in 2015. 
  Washington, DC - 1/17/2015
• An Evolving Landscape: Treatment of Castrate Resistant Prostate Cancer. 
  JW Marriott Hotel, Scottsdale, AZ - 1/25/2014
• Medical Complications of Systemic Therapy for Prostate Cancer. 
  Nashville, TN - 1/20/2014
• Role of Systemic Therapy in Bladder Cancer 
  Vanderbilt-Ingram Cancer Center - 1/8/2014
• Approaches to asymptomatic metastatic castration-resistant prostate cancer. 
  New York, NY - 1/4/2014
• Prostate Cancer Survivorship - What every man should know. 
  Newton Marriott Hotel, Newton, MA - 1/18/2012
• Join now to see all